Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke

• Published in: Journal of neuroimmunology 2010-10, Vol.227 (1), p.93-100
• Main Authors: Shin, Jin A, Lee, Hyunah, Lim, Yoo-Kyoung, Koh, Yaekyu, Choi, Ji Ha, Park, Eun-Mi
• Format: Article
• Language: English
• Subjects: Acute Disease; Acute ischemic stroke; Allergy and Immunology; Animals; Brain Infarction - drug therapy; Brain Infarction - immunology; Brain Infarction - metabolism; Brain injury; Brain Ischemia - drug therapy; Brain Ischemia - immunology; Brain Ischemia - metabolism; Disease Models, Animal; Dose-Response Relationship, Immunologic; Female; Inflammation Mediators - antagonists & inhibitors; Inflammation Mediators - therapeutic use; Male; Mice; Mice, Inbred C57BL; Microglial activation; Neurology; Neuroprotective Agents - therapeutic use; Pro-inflammatory cytokines; Reactive oxygen species; Reactive Oxygen Species - metabolism; Resveratrol; Sex difference; Stilbenes - therapeutic use; Stroke - drug therapy; Stroke - immunology; Stroke - metabolism
• ISSN: 0165-5728; 1872-8421
• DOI: 10.1016/j.jneuroim.2010.06.017

Abstract We defined whether resveratrol administration during the acute phase of ischemic stroke reduces brain injury in mice. Infarct volumes were decreased significantly in both sexes with different doses of resveratrol (5 mg/kg for males and 1 mg/kg for females) administered 3 h after ischemic stroke. Administration of resveratrol 6 h after insult was also effective to decrease infarct volumes. Resveratrol suppressed expressions of IL-1β and TNF-α, microglial activation, and ROS production in the ischemic cortex. The findings suggest that the suppression of inflammation is partly associated with the neuroprotective effects of resveratrol, and resveratrol can be developed as a therapeutic drug for acute ischemic stroke.